Search results
Showing 571 to 585 of 1331 results for heart OR cardi* OR arrythmia
applicable) Source guidance details Comes from guidance Heart valve disease presenting in adults: investigation and management Number
In development Reference number: GID-TA11544 Expected publication date: 14 May 2026
CytoSorb for reducing risk of bleeding during cardiac surgery
Topic prioritisation
Is obesity an independent risk factor for perinatal morbidity and mortality?
explanatory notes(if applicable) It is more difficult to monitor fetal heart rate, uterine contractions and fetal position in women who...
Evidence-based recommendations on artificial intelligence (AI)-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images.
Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTG676)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders.
Discontinued Reference number: GID-MT130
Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura in adults, and in young people aged 12 years and over who weigh at least 40 kg.
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management (CG84)
This guideline covers diagnosing, managing and referring infants and young children younger than 5 years who present with acute diarrhoea (lasting up to 14 days) with or without vomiting. It aims to improve the diagnosis and management of infective gastroenteritis and appropriate escalation of care.
Evidence-based recommendations on gammaCore for cluster headache.
repaired valves. Source guidance details Comes from guidance Heart valve disease presenting in adults: investigation and management...
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.
We have moved interventional procedures guidance 602 to become HealthTech guidance 459. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.